• About Us
    • CEO’s comment
    • NOV Summary
    • Key Members
    • Advisory Board
    • Scientific Advisory Board
  • Pipeline
  • Partnering
    • Partnering Models
    • Partners
  • Information
    • News
    • Press release
  • Contact Us
  • HOME
  • CONTACT US
  • SITEMAP
  • KOR
  • ENG
  • HOME
  • CONTACT US
  • SITEMAP
  • KOR
  • ENG

항암 신약 개발

  • About Us
    • CEO’s comment
    • NOV Summary
    • Key Members
    • Advisory Board
    • Scientific Advisory Board
  • Pipeline
  • Partnering
    • Partnering Models
    • Partners
  • Information
    • News
    • Press release
  • Contact Us
search
  • home
  • Home
  • Government-FundedVirtual Oncology Drug Development

    Challenge for
    Global Oncology
    Drug DevelopmentREAD MORE

  • Government-FundedVirtual Oncology Drug Development

    Globally CompetitiveDrug PipelineREAD MORE

  • Government-FundedVirtual Oncology Drug Development

    Win WinPartnering ModelREAD MORE

  • 1
  • 2
  • 3
  • Prev
  • Pause/Play
  • Next
  • About NOV
  • News

    “Liquid Biopsy for Therapeutic Monitoring: New Area of Companion Diagnosti..
    2018-10-10
    more
  • Press release

    TRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive Gl..
    2018-12-05
    more

NOV Pipeline

  • Product
  • Indication
  • Target
  • Nonclinical
  • Phase 1
  • Phase 2
    • antibodyNOV1105

    • Solid cancers (Ovarian, Melanoma)
    • HGF
    • antibodyNOV1201 (Licensed Out)

    • NSCLC, Breast cancer
    • Pan-HER
    • antibodyNOV1204

    • Solid tumors
    • Tubulin
    • antibodyNOV1301

    • HCC & MDS
    • ALK-5 (TGFβ type I receptor)
    • antibodyNOV1401

    • Solid tumors
    • PARP1/2
    • antibodyNOV1402

    • Solid tumors
    • PARP/TNKS
    • antibodyNOV1501 (Licensed Out)

    • Solid tumors
    • DLL4/VEGF
    • antibodyNOV1601

    • Solid tumors with TRK gene rearrangements or certain TRK mutations
    • Pan TRK
    • antibodyNOV1701

    • Solid tumors & Hematologic tumors
    • Myc
    • antibodyNOV1702

    • HPV-associated disease (CIN, cervical cancer)
    • E6 and E7 of HPV 16, 18 type
    • antibodyNOV1801

    • Solid tumors
    • 4-1BB/TNFRSF9/CD137
    • antibodyNOV1802

    • Solid tumors
    • tumor-related multitargets
    • antibodyNOV1803

    • Solid tumors
    • CEACAM6 (CD66c)
antibody : Antibody small_molecule : Small molecule small_molecule : Gene therapy small_molecule : Cell therapy small_molecule : etc
  • FAMILY SITE
    • National Cancer Center
    • Ministry of Health and Welfare
    • Korea Health Industry Development Institute
5th floor of Geomjin Buidling. National Cancer Center, 323 Ilsan-ro, Isandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea
Copyright © National Cancer Center. All Rights Reserved.
국립암센터